Exhibit 10.10
V VITEX
February 16, 2000
By Facsimile and Certified Mail
Xxxx XxXxxxxxxx
Director, Office of Patents & Licenses
Commercial Development
The New York Blood Center, Inc.
000 X. 00xx Xxxxxx
Xxx Xxxx, XX 00000-0000
Re: Exclusive License Agreement (#5) for Virally Inactivated Cellular Products
Dear Xxxx,
Pursuant to Section 10.5 of the Exclusive License Agreement (#5) for Virally
Inactivated Cellular Products between The New York Blood Center, Inc. ("NYBC")
and V.I. Technologies, Inc. ("Vitex"), dated September 21, 1995, as amended
("Agreement"), Vitex hereby notifies NYBC that it is terminating the Agreement
effective February 1, 2000.
VITEX will return all know-how related to phthalocyanines to NYBC.
Should you have any questions regarding this matter, please contact me at
617.864.4800 x240.
Sincerely,
/s/ Xxxxxx X. Xxxxxxxx
Xxxxxx X. Xxxxxxx
Director, Business Development
cc: General Counsel, The New York Blood Center, Inc.
Xxxx Xxxx, VITEX
Xxx Xxxxxxx, VITEX
Xxxxx Xxxxxxx, Pall Corporation
